Unicycive Therapeutics, Inc. (UNCY) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Unicycive Therapeutics reported revenue of $0. Net income was -$26.6M, or -$1.67 per diluted share. Operating activities generated -$31.3M of cash, leaving -$31.3M of free cash flow. At fiscal year end, Unicycive Therapeutics held $49.1M in total assets against $18.9M in total liabilities, including $29.2M of cash and equivalents.
Open the full interactive Unicycive Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Unicycive Therapeutics Key Stats
| Share Price | $3.73 |
|---|---|
| Market Cap | $100.4M |
| 52-Week Range | $3.73 – $8.56 |
| Shares Outstanding | 26.9 million (basic, 2026 Q2) |
Unicycive Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $951,000 | $675,000 | — | $0 |
| Operating Income | -$9.0M | -$18.1M | -$20.8M | -$32.1M | -$29.5M |
| Pre-Tax Income | -$10.0M | -$18.1M | -$30.5M | -$36.7M | -$26.6M |
| Net Income | -$10.0M | -$18.1M | -$30.5M | -$36.7M | -$26.6M |
| Diluted EPS | — | -$12.00 | -$12.80 | -$5.60 | -$1.67 |
Unicycive Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$6.0M | -$14.7M | -$12.8M | -$1.7M |
| Diluted EPS | -$0.33 | -$0.92 | -$0.54 | -$0.06 |
Unicycive Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $16.6M | $455,000 | — | — | $29.2M |
| Current Assets | $18.4M | $2.6M | $13.4M | $30.9M | $49.0M |
| Total Assets | $18.7M | $2.8M | $14.2M | $31.7M | $49.1M |
| Current Liabilities | $2.1M | $3.3M | $17.5M | $24.1M | $18.9M |
| Total Liabilities | $2.3M | $3.3M | $18.0M | $24.2M | $18.9M |
| Shareholders' Equity | $16.5M | -$466,000 | -$3.8M | $7.4M | $30.2M |
Unicycive Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$5.8M | -$15.7M | -$18.3M | -$28.6M | -$31.3M |
| Cash From Investing | -$29,000 | -$2,000 | -$12,000 | -$72,000 | -$12.1M |
| Cash From Financing | $22.4M | -$471,000 | $27.5M | $45.1M | $46.5M |
| Free Cash Flow | — | -$15.7M | -$18.3M | -$28.6M | -$31.3M |
| Dividends Paid | — | — | $900,000 | $1.1M | — |
Figures from Unicycive Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Unicycive Therapeutics financials page for every line item.
Unicycive Therapeutics Company Profile
| Ticker | UNCY |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Mountain View, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001766140 |
Frequently Asked Questions
What was Unicycive Therapeutics' revenue in fiscal 2025?
Unicycive Therapeutics (UNCY) reported revenue of $0 for fiscal 2025.
What is Unicycive Therapeutics' annual revenue history?
Unicycive Therapeutics' annual revenue by fiscal year: 2021: $0; 2022: $951,000; 2023: $675,000; 2025: $0.
What was Unicycive Therapeutics' net income in fiscal 2025?
Unicycive Therapeutics reported net income of -$26.6M for fiscal 2025.
What was Unicycive Therapeutics' earnings per share (EPS) in fiscal 2025?
Unicycive Therapeutics' diluted EPS was -$1.67 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Unicycive Therapeutics generate in fiscal 2025?
Unicycive Therapeutics generated -$31.3M of free cash flow in fiscal 2025.
What was Unicycive Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Unicycive Therapeutics reported revenue of $0.
How many shares of Unicycive Therapeutics are outstanding?
Unicycive Therapeutics reported a weighted average of 26.9 million basic shares outstanding in 2026 Q2.
What is Unicycive Therapeutics' market cap?
Based on its latest closing price, Unicycive Therapeutics (UNCY) has a market capitalization of about $100.4M.
When does Unicycive Therapeutics' fiscal year end?
Unicycive Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Unicycive Therapeutics headquartered?
Unicycive Therapeutics lists its business address in Mountain View, California in its SEC filings.